Facing ‘Daunting’ Launch Schedule, Moderna to Slash $4B in R&D Spend by 2028

During an investor day Thursday, Moderna’s R&D chief Stephen Hoge detailed plans for the famed biotech to trim R&D spending in preparation for the launch of up to 10 new products.